Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study
DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease
2018 ◽
Vol 12
(supplement_1)
◽
pp. S034-S034
◽
2018 ◽
Vol 12
(supplement_1)
◽
pp. S278-S278
◽
2017 ◽
Vol 47
(4)
◽
pp. 485-493
◽
2019 ◽
Vol 13
(Supplement_1)
◽
pp. S525-S525
Keyword(s):
2017 ◽
Vol 152
(8)
◽
pp. 1975-1984.e8
◽
Keyword(s):